Research Article
Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer
Table 8
The number of IC50 verified drugs and potential drugs identified by using ES, cMap value less than 0.1 and 0.5 for early- and late-stage NSCLC.
| |||||||||||||||||||||
Numbers before and after the slash sign (/) denote the numbers of IC50 verified drugs and potential drugs, respectively. |